Clinical

Dataset Information

0

Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer


ABSTRACT: This study is to evaluate the disease control rate and time to progression of the sequential combination of oxaliplatin with an alternative anti-metabolite Trifluridine/tipiracil hydrochloride mixture, TAS-102,(TAS-OX) as well as irinotecan in combination with TAS-102 oxaliplatin(TAS-OX) + Bevacizumab in late-line metastatic colorectal cancer (mCRC)

DISEASE(S): Colon Cancer,Colorectal Neoplasms,Rectal Cancer

PROVIDER: 14404 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2024-08-26 | GSE275628 | GEO
| 2220958 | ecrin-mdr-crc
2023-03-31 | GSE226221 | GEO
| 91504 | ecrin-mdr-crc
| 2332004 | ecrin-mdr-crc
| 92106 | ecrin-mdr-crc
| 2260946 | ecrin-mdr-crc
2016-01-31 | GSE29839 | GEO
| PRJNA746774 | ENA
2016-01-31 | GSE29840 | GEO